Which has stronger valuation & earnings, OCGN or MRNA?

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 108.23 -$67.85M -$0.24 N/A Moderna $1.94B 13.68 -$2.82B -$8.15 N/A

Is OCGN or MRNA more profitable?

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Moderna -143.55% -26.64% -19.32%

Does the media refer more to OCGN or MRNA?

In the previous week, Moderna had 19 more articles in the media than Ocugen. MarketBeat recorded 23 mentions for Moderna and 4 mentions for Ocugen. Moderna's average media sentiment score of 0.82 beat Ocugen's score of 0.47 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 10 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, OCGN or PFE?

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 108.23 -$67.85M -$0.24 N/A Pfizer $62.58B 2.23 $7.77B $1.31 18.67

Is OCGN or PFE more profitable?

Pfizer has a net margin of 11.83% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.44% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Pfizer 11.83% 19.44% 8.41%

Does the media prefer OCGN or PFE?

In the previous week, Pfizer had 79 more articles in the media than Ocugen. MarketBeat recorded 83 mentions for Pfizer and 4 mentions for Ocugen. Ocugen's average media sentiment score of 0.47 beat Pfizer's score of 0.44 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pfizer 37 Very Positive mention(s) 9 Positive mention(s) 14 Neutral mention(s) 13 Negative mention(s) 6 Very Negative mention(s) Neutral

Is STOK or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Stoke Therapeutics -529.20% -48.84% -42.27% Ocugen N/A -127,987.80% -135.48%

Does the media prefer STOK or OCGN?

In the previous week, Stoke Therapeutics had 2 more articles in the media than Ocugen. MarketBeat recorded 6 mentions for Stoke Therapeutics and 4 mentions for Ocugen. Stoke Therapeutics' average media sentiment score of 1.07 beat Ocugen's score of 0.47 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OCGN or SRPT more profitable?

Ocugen has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Sarepta Therapeutics -2.94% 7.56% 2.94%

Does the media refer more to OCGN or SRPT?

In the previous week, Sarepta Therapeutics had 16 more articles in the media than Ocugen. MarketBeat recorded 20 mentions for Sarepta Therapeutics and 4 mentions for Ocugen. Ocugen's average media sentiment score of 0.47 beat Sarepta Therapeutics' score of 0.05 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Is AMLX or OCGN more profitable?

Amylyx Pharmaceuticals' return on equity of -55.69% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -55.69% -50.73% Ocugen N/A -127,987.80% -135.48%

Does the media prefer AMLX or OCGN?

In the previous week, Amylyx Pharmaceuticals and Amylyx Pharmaceuticals both had 4 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Ocugen's score of 0.47 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ocugen (OCGN) Competitors

$1.41 -0.06 (-4.08%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$1.40 0.00 (-0.35%)

As of 08:09 AM Eastern

Compare

OCGN vs. MRNA, PFE, STOK, SRPT, and AMLX

Should you buy Ocugen stock or one of its competitors? MarketBeat compares Ocugen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocugen include Moderna (MRNA), Pfizer (PFE), Stoke Therapeutics (STOK), Sarepta Therapeutics (SRPT), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "medical" sector.

How does Ocugen compare to Moderna?

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

In the previous week, Moderna had 19 more articles in the media than Ocugen. MarketBeat recorded 23 mentions for Moderna and 4 mentions for Ocugen. Moderna's average media sentiment score of 0.82 beat Ocugen's score of 0.47 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	10 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocugen has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Ocugen currently has a consensus target price of $9.50, suggesting a potential upside of 573.76%. Moderna has a consensus target price of $38.27, suggesting a potential downside of 42.89%. Given Ocugen's stronger consensus rating and higher probable upside, equities analysts clearly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	108.23	-$67.85M	-$0.24	N/A
Moderna	$1.94B	13.68	-$2.82B	-$8.15	N/A

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Moderna	-143.55%	-26.64%	-19.32%

10.3% of Ocugen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Ocugen beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Ocugen compare to Pfizer?

Ocugen (NASDAQ:OCGN) and Pfizer (NYSE:PFE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Ocugen currently has a consensus target price of $9.50, indicating a potential upside of 573.76%. Pfizer has a consensus target price of $28.50, indicating a potential upside of 16.51%. Given Ocugen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ocugen is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Pfizer has a net margin of 11.83% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.44% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Pfizer	11.83%	19.44%	8.41%

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 4.0% of Ocugen shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	108.23	-$67.85M	-$0.24	N/A
Pfizer	$62.58B	2.23	$7.77B	$1.31	18.67

Ocugen has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

In the previous week, Pfizer had 79 more articles in the media than Ocugen. MarketBeat recorded 83 mentions for Pfizer and 4 mentions for Ocugen. Ocugen's average media sentiment score of 0.47 beat Pfizer's score of 0.44 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	37 Very Positive mention(s)	9 Positive mention(s)	14 Neutral mention(s)	13 Negative mention(s)	6 Very Negative mention(s)	Neutral

Summary

Pfizer beats Ocugen on 10 of the 16 factors compared between the two stocks.

How does Ocugen compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Ocugen has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Ocugen	N/A	-127,987.80%	-135.48%

10.3% of Ocugen shares are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by company insiders. Comparatively, 4.0% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Stoke Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market.

In the previous week, Stoke Therapeutics had 2 more articles in the media than Ocugen. MarketBeat recorded 6 mentions for Stoke Therapeutics and 4 mentions for Ocugen. Stoke Therapeutics' average media sentiment score of 1.07 beat Ocugen's score of 0.47 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Stoke Therapeutics has higher revenue and earnings than Ocugen. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A
Ocugen	$4.41M	108.23	-$67.85M	-$0.24	N/A

Stoke Therapeutics presently has a consensus target price of $42.00, suggesting a potential upside of 42.57%. Ocugen has a consensus target price of $9.50, suggesting a potential upside of 573.76%. Given Ocugen's higher possible upside, analysts clearly believe Ocugen is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Stoke Therapeutics beats Ocugen on 9 of the 16 factors compared between the two stocks.

How does Ocugen compare to Sarepta Therapeutics?

Ocugen (NASDAQ:OCGN) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Ocugen has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

Ocugen has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

10.3% of Ocugen shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Sarepta Therapeutics had 16 more articles in the media than Ocugen. MarketBeat recorded 20 mentions for Sarepta Therapeutics and 4 mentions for Ocugen. Ocugen's average media sentiment score of 0.47 beat Sarepta Therapeutics' score of 0.05 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sarepta Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Ocugen has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	108.23	-$67.85M	-$0.24	N/A
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$0.96	N/A

Ocugen currently has a consensus price target of $9.50, indicating a potential upside of 573.76%. Sarepta Therapeutics has a consensus price target of $25.09, indicating a potential upside of 33.32%. Given Ocugen's stronger consensus rating and higher probable upside, research analysts clearly believe Ocugen is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sarepta Therapeutics	7 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

Ocugen beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Ocugen compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Amylyx Pharmaceuticals currently has a consensus price target of $24.25, indicating a potential upside of 39.29%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 573.76%. Given Ocugen's higher possible upside, analysts clearly believe Ocugen is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Amylyx Pharmaceuticals has a beta of -0.2, meaning that its share price is 120% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market.

Amylyx Pharmaceuticals' return on equity of -55.69% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Ocugen	N/A	-127,987.80%	-135.48%

In the previous week, Amylyx Pharmaceuticals and Amylyx Pharmaceuticals both had 4 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 1.87 beat Ocugen's score of 0.47 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ocugen	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocugen has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	22.16	-$144.74M	-$1.50	N/A
Ocugen	$4.41M	108.23	-$67.85M	-$0.24	N/A

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Amylyx Pharmaceuticals beats Ocugen on 9 of the 15 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCGN vs. The Competition

Export

Metric	Ocugen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$497.63M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-5.88	20.85	27.12	24.26
Price / Sales	108.23	314.01	587.25	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	-35.25	8.49	10.89	6.29
Net Income	-$67.85M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.00%	-3.56%	-2.11%	-1.35%
1 Month Performance	16.53%	6.31%	3.28%	-0.64%
1 Year Performance	27.03%	48.30%	26.33%	19.08%

Ocugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCGN Ocugen	2.3773 of 5 stars	$1.41 -4.1%	$9.50 +573.8%	+23.7%	$497.63M	$4.41M	N/A	80	News Coverage Gap Down
MRNA Moderna	1.8647 of 5 stars	$81.80 +2.6%	$37.13 -54.6%	+99.2%	$31.65B	$1.94B	N/A	4,700
PFE Pfizer	4.3015 of 5 stars	$23.74 -2.4%	$28.59 +20.4%	-4.6%	$138.61B	$62.58B	18.12	75,000	Trending News Analyst Forecast
STOK Stoke Therapeutics	2.4463 of 5 stars	$32.43 -0.8%	$41.83 +29.0%	+148.4%	$2.04B	$184.42M	N/A	100	News Coverage Positive News Analyst Forecast
SRPT Sarepta Therapeutics	2.9206 of 5 stars	$19.18 -0.5%	$24.81 +29.4%	+3.6%	$2.04B	$2.20B	N/A	1,372

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCGN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, STOK, SRPT, and AMLX

How does Ocugen compare to Moderna?

Summary

How does Ocugen compare to Pfizer?

Summary

How does Ocugen compare to Stoke Therapeutics?

Summary

How does Ocugen compare to Sarepta Therapeutics?

Summary

How does Ocugen compare to Amylyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, STOK, SRPT, and AMLX

How does Ocugen compare to Moderna?

Does the media refer more to OCGN or MRNA?

Which has more volatility & risk, OCGN or MRNA?

Do analysts recommend OCGN or MRNA?

Which has stronger valuation & earnings, OCGN or MRNA?

Is OCGN or MRNA more profitable?

Do insiders and institutionals have more ownership in OCGN or MRNA?

Summary

How does Ocugen compare to Pfizer?

Do analysts recommend OCGN or PFE?

Is OCGN or PFE more profitable?

Do insiders & institutionals believe in OCGN or PFE?

Which has higher valuation & earnings, OCGN or PFE?

Which has more volatility and risk, OCGN or PFE?

Does the media prefer OCGN or PFE?

Summary

How does Ocugen compare to Stoke Therapeutics?

Is STOK or OCGN more profitable?

Do institutionals and insiders have more ownership in STOK or OCGN?

Which has more risk & volatility, STOK or OCGN?

Does the media prefer STOK or OCGN?

Which has higher valuation and earnings, STOK or OCGN?

Do analysts prefer STOK or OCGN?

Summary

How does Ocugen compare to Sarepta Therapeutics?

Which has more volatility and risk, OCGN or SRPT?

Is OCGN or SRPT more profitable?

Do institutionals & insiders believe in OCGN or SRPT?

Does the media refer more to OCGN or SRPT?

Which has stronger earnings and valuation, OCGN or SRPT?

Do analysts rate OCGN or SRPT?

Summary

How does Ocugen compare to Amylyx Pharmaceuticals?

Do analysts prefer AMLX or OCGN?

Which has more risk & volatility, AMLX or OCGN?

Is AMLX or OCGN more profitable?

Does the media prefer AMLX or OCGN?

Which has preferable valuation and earnings, AMLX or OCGN?

Do institutionals and insiders have more ownership in AMLX or OCGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools